



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Copaescu, A;Rose, M;Mouhtouris, E;Chua, KY;Holmes, NE;Phillips, EJ;Trubiano, JA

Title:

Delayed hypersensitivity associated with amoxicillin-clavulanate

Date:

2020-10-01

Citation:

Copaescu, A., Rose, M., Mouhtouris, E., Chua, K. Y., Holmes, N. E., Phillips, E. J. & Trubiano, J. A. (2020). Delayed hypersensitivity associated with amoxicillin-clavulanate. *Allergy European Journal of Allergy and Clinical Immunology*, 75 (10), pp.2700-2702. <https://doi.org/10.1111/all.14359>.

Persistent Link:

<https://hdl.handle.net/11343/275786>

1
2 DR. ANA COPAESCU (Orcid ID : 0000-0002-9183-5032)

3
4
5 Article type : Letter to the Editor

6
7
8 Corresponding author mail id : ana.copaescu@gmail.com

9
10 **Title:** Delayed Hypersensitivity associated with Amoxicillin-Clavulanate

11
12
13 To the Editor,

14
15 Beta-lactam/beta-lactamase combinations are prevalently used in hospital-acquired infections
16 and prescribing data suggests that drugs such as amoxicillin-clavulanate are amongst the most
17 commonly prescribed antibiotics in the community [1][2]. Selective immediate reactions to
18 clavulanate have been well described particularly from Southern Europe, however, little is
19 known about selective delayed reactions [3]. We report on a novel cohort of patients with a
20 history of delayed reaction to amoxicillin-clavulanate who demonstrated a delayed intradermal
21 skin test response to clavulanate.

22 Patients reporting a delayed amoxicillin-clavulanate allergy phenotype that completed beta-
23 lactam skin prick (SPT) and intradermal testing (IDT) at the Drug and Antibiotic Allergy
24 Services of Austin Health and Peter MacCallum Cancer Centre (VIC, Australia) between 1st May
25 2015 and 1st February 2019 were identified from a prospectively collected database. Patients
26 underwent SPT/IDT followed by oral provocation as per a standardised previously published
27 beta-lactam protocol, including validated Diater reagents (DAP; Madrid, Spain) which was used
28 for the major (benzylpenicilloyl-poyl-L-lysine [PPL]) and minor determinant mixtures (MDM)
29 and clavulanate [4]. In addition, IDT was performed to clavulanate (2 mg/ml or 5 mg/ml and 20

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/ALL.14359](https://doi.org/10.1111/ALL.14359)

This article is protected by copyright. All rights reserved

30 mg/ml) for selected patients (not routinely available at our service). A positive delayed IDT test
31 was a >5 mm erythematous, raised and indurated or infiltrative lesion present at 6 to 48 hours
32 post IDT (at the site of IDT) [5]. Oral provocation in patients with a positive clavulanate
33 intradermal test was undertaken with phenoxymethylpenicillin potassium (5-day provocation)
34 and amoxicillin (5-day provocation). In patients with confirmed clavulanate hypersensitivity
35 peripheral blood mononuclear cells (PBMCs) were isolated from whole heparinized blood and
36 stored at -80C in 90% heat inactivated foetal bovine serum (FBS) and 10% dimethyl sulfoxide
37 until IFN- γ release Enzyme linked ImmunoSpot (ELISpot) assay analysis was performed as per
38 previously published methods [6]. The mean number of spots for the test and unstimulated wells
39 was calculated. A positive response was defined as equal or greater to 50 spot forming unit
40 (SFU)/million cells after background (unstimulated control) removal (dotted line) (**Supplement**
41 **Figure 1**) [7].

42 From the prospective cohort of 1069 patients, we identified 66 (6.2%) patients reporting an
43 adverse drug reaction (ADR) temporally associated with amoxicillin-clavulanate. Among these,
44 30 (45.5%) reported delayed hypersensitivity, 23 (34.8%) immediate hypersensitivity and 13
45 (12.1%) a non-immune mediated or unknown reaction. For the non-immune mediated or
46 unknown reactions, 11 (11/13; 84.6%) had the allergy label removed without testing. Concerning
47 the patients with immediate amoxicillin-clavulanate hypersensitivity skin test positivity, 6 (26%)
48 patients had positive skin testing to ampicillin and 2 (8.6%) to clavulanate. From the 30 with a
49 reported delayed amoxicillin-clavulanate hypersensitivity, 18 (60%) underwent testing with
50 clavulanate in addition to the routine beta-lactam protocol. Six (33.3%) patients were positive to
51 clavulanate at either concentration on IDT (**Table 1**). For the six patients that tested positive to
52 clavulanate, one was positive to both ampicillin and clavulanate (**Table 1: ID 6**). From those that
53 had an isolated clavulanate IDT positive (n = 5), 4/5 tolerated amoxicillin and penicillin oral
54 provocation and one (**Table 1: ID 2**) refused amoxicillin challenge but tolerated
55 phenoxymethylpenicillin potassium and cefuroxime 5-day oral challenge. Overall, in those
56 patients with an immune mediated amoxicillin-clavulanate allergy history (n = 53), 6 (11.3%)
57 were confirmed on clavulanate skin testing. An example of a positive skin test is demonstrated in
58 **Figure 1**.

59 We found that 2 patients (33%) were positive (**Table 1: ID 1, 2**) to clavulanate on ELISpot
60 testing (**Supplement Figure 1**) utilizing previously published criterion [6]. One of the patients

61 presented borderline positive response at 50 SFU/million cells and might reflect a false positive
62 result or low activated peripheral T-cell numbers. These findings are possibly related to the delay
63 between the skin eruption and the allergy investigations. Also, new data demonstrates that
64 resident memory T cells in the skin are likely to be a major player in the reproducibility of skin
65 testing, where peripheral blood may be unreactive [8]. Furthermore, we note that the amoxicillin-
66 clavulanate ELISpot was negative in those with positive ELISpot to clavulanate. This may be
67 related to a lower immunogenicity of amoxicillin-clavulanate or to the fact that this combination
68 generates different haptenated proteins than clavulanate alone. The ELISpot results for the cohort
69 are demonstrated in Supplementary materials (**Supplement Figure 1**).

70
71 Isolated clavulanate hypersensitivity has been reported in the literature. A Portuguese
72 prospective cohort (7-year period) examined severe IgE-mediated hypersensitivity to
73 clavulanate. In their cohort of 166 patients, they identified 6 (3.6%) cases of isolated immediate
74 clavulanic acid allergy confirmed by either skin testing or positive oral challenge [3]. In this
75 specific cohort, the authors identified that selective allergy to clavulanate represented 5 of all
76 immediate reactions to beta-lactams (N = 32) highlighting the need for clavulanate allergy
77 assessment. Lezmi and colleagues identified, from a pediatric cohort, 11 cases of isolated
78 delayed hypersensitivity to clavulanate based on positive prolonged amoxicillin-clavulanate
79 provocation and associated negative amoxicillin challenges [9, 10]. In an adult population study
80 summarizing results of penicillin allergy testing, 5 cases of isolated clavulanate allergy were
81 described (intradermal clavulanate positive/amoxicillin challenge negative) [10]. In this cohort
82 (N = 5), 80% of reactions were immediate allergy phenotypes. Finally, several case reports
83 described isolated clavulanate delayed hypersensitivity of varied severity from mild skin
84 eruptions [11] to acute generalized exanthematous pustulosis [11, 12]. There are limited reports
85 of delayed clavulanate hypersensitivity, also confirmed by IFN- γ release Enzyme Linked
86 ImmunoSpot Assay.

87
88 In summary, we identified that 3% of prospective antibiotic allergy tested cohort reported a
89 delayed amoxicillin-clavulanate hypersensitivity, 13% of which had a confirmed isolated
90 clavulanate hypersensitivity. Previous published reports have confirmed immediate clavulanate
91 hypersensitivity [1, 13, 14], however literature detailing cases of skin test or *ex vivo* diagnostic

92 confirmed delayed hypersensitivity are uncommon. Further, infrequently reported in the
93 literature is dual sensitization to amoxicillin and clavulanate [15], also demonstrated in a single
94 patient in our cohort. Clinicians should be alert to patients reporting amoxicillin-clavulanate
95 allergies and the potential for an isolated hypersensitivity, ensuring the beta-lactam “window”
96 does not necessarily close on this patient cohort forever.

97

98 This study was approved by the Austin Health ethics committee and the investigators obtained
99 written informed consent from the participants.

100

101

- 102 1. Confino-Cohen, R., et al., *The Importance of Amoxicillin and Amoxicillin-Clavulanate*
103 *Determinants in the Diagnosis of Immediate Allergic Reactions to beta-Lactams*. Int Arch
104 Allergy Immunol, 2016. **170**(1): p. 62-6.
- 105 2. ACSQHC. *AURA 2017*. Second Australian report on antimicrobial use and resistance in
106 human health 2017 [cited 2019 24/3/2019]; Available from:
107 [https://www.safetyandquality.gov.au/wp-content/uploads/2018/01/AURA-2017-Second-](https://www.safetyandquality.gov.au/wp-content/uploads/2018/01/AURA-2017-Second-Australian-report-on-Antimicrobial-Use-and-Resistance-in-human-health.pdf)
108 [Australian-report-on-Antimicrobial-Use-and-Resistance-in-human-health.pdf](https://www.safetyandquality.gov.au/wp-content/uploads/2018/01/AURA-2017-Second-Australian-report-on-Antimicrobial-Use-and-Resistance-in-human-health.pdf).
- 109 3. Silveira, A.M., et al., *Anaphylaxis to Clavulanic Acid: A 7-Year Survey*. J Investig
110 Allergol Clin Immunol, 2019. **29**(4): p. 311-313.
- 111 4. Trubiano, J.A., et al., *Impact of an Integrated Antibiotic Allergy Testing Program on*
112 *Antimicrobial Stewardship: A Multicenter Evaluation*. Clin Infect Dis, 2017. **65**(1): p.
113 166-174.
- 114 5. Romano, A., et al., *Diagnosis of nonimmediate reactions to beta-lactam antibiotics*.
115 Allergy, 2004. **59**(11): p. 1153-60.
- 116 6. Trubiano, J.A., et al., *The Combined Utility of Ex Vivo IFN-gamma Release Enzyme-*
117 *Linked ImmunoSpot Assay and In Vivo Skin Testing in Patients with Antibiotic-*
118 *Associated Severe Cutaneous Adverse Reactions*. J Allergy Clin Immunol Pract, 2018.
119 **6**(4): p. 1287-1296 e1.
- 120 7. Keane, N.M., et al., *High-avidity, high-IFN-gamma-producing CD8 T-cell responses*
121 *following immune selection during HIV-1 infection*. Immunol Cell Biol, 2012. **90**(2): p.
122 224-34.

- 123 8. Trubiano, J.A., et al., *Analysis of Skin-Resident Memory T Cells Following Drug*
124 *Hypersensitivity Reactions*. J Invest Dermatol, 2019.
- 125 9. Lezmi, G., et al., *Non-immediate-reading skin tests and prolonged challenges in non-*
126 *immediate hypersensitivity to beta-lactams in children*. Pediatr Allergy Immunol, 2018.
127 **29**(1): p. 84-89.
- 128 10. Meng, J., D. Thursfield, and J.J. Lukawska, *Allergy test outcomes in patients self-*
129 *reported as having penicillin allergy: Two-year experience*. Ann Allergy Asthma
130 Immunol, 2016. **117**(3): p. 273-9.
- 131 11. Bonadonna, P., et al., *Delayed selective reaction to clavulanic acid: a case report*. J
132 Invest Allergol Clin Immunol, 2005. **15**(4): p. 302-4.
- 133 12. Amaral, L., L. Carneiro-Leao, and J.R. Cernadas, *Acute Generalized Exanthematous*
134 *Pustulosis Due to Clavulanic Acid*. J Allergy Clin Immunol Pract, 2019.
- 135 13. Torres, M.J., et al., *Clavulanic acid can be the component in amoxicillin-clavulanic acid*
136 *responsible for immediate hypersensitivity reactions*. J Allergy Clin Immunol, 2010.
137 **125**(2): p. 502-505 e2.
- 138 14. Sanchez-Morillas, L., et al., *Selective allergic reactions to clavulanic acid: a report of 9*
139 *cases*. J Allergy Clin Immunol, 2010. **126**(1): p. 177-9.
- 140 15. Salas, M., et al., *Patients Taking Amoxicillin-Clavulanic Can Become Simultaneously*
141 *Sensitized to Both Drugs*. J Allergy Clin Immunol Pract, 2017. **5**(3): p. 694-702 e3.

142

143

144 Corresponding author: Copaescu A^{1*}

145 Copaescu A^{1*}

146 Rose M^{1,2,3*}

147 Mouhtouris E¹

148 Chua KY¹

149 Holmes NE¹

150 Phillips EJ^{4,5}

151 Trubiano JA^{1,2,3,6}

152

- 153 1. Centre for Antibiotic Allergy and Research, Department of Infectious Diseases, Austin
154 Health, Heidelberg, Victoria, Australia
- 155 2. The National Centre for Infections in Cancer, Peter MacCallum Cancer Centre,
156 Melbourne, Victoria, Australia
- 157 3. Department of Oncology, Sir Peter MacCallum Cancer Centre, The University of
158 Melbourne, Parkville, Victoria, Australia
- 159 4. Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch,
160 Western Australia, Australia
- 161 5. Department of Infectious Diseases, Vanderbilt University Medical Centre, Nashville,
162 Tennessee, USA.
- 163 6. Department of Medicine (Austin Health), The University of Melbourne, Heidelberg,
164 Australia.

165
166
167
168 **Funding sources**

169 None

170
171 **Acknowledgements**

172 Dr. Copaescu has nothing to disclose.

173 Dr. Rose has nothing to disclose.

174 Dr. Mouhtouris has nothing to disclose.

175 Dr. Chua has nothing to disclose.

176 Dr. Holmes has nothing to disclose.

177 Dr. Phillips reports grants from NHMRC Australia, grants from NIH, personal fees from
178 Uptodate, personal fees from Biocryst, from Patent for HLA-B*57:01 testing for abacavir HSR,
179 other from Aicuris, grants from ACH2 Australia, personal fees from Xcovery, personal fees from
180 Medicines for Malaria (MMV), other from Provisional patent pending for HLA-A*32:01 testing
181 for Vancomycin hypersensitivity, outside the submitted work; In addition, Dr. Phillips has a
182 patent Patent issued for HLA-B*57:01 testing for abacavir hypersensitivity to IIID Pty Ltd. I am
183 a co-director of this company to which the patent was issued issued.

Author Manuscript

Table 1: Baseline and clinical characteristics of patients with a positive **delayed** intradermal test to clavulanate.

ID	Age/Sex	ICH	Phenotype [∇]	RegiSCAR	Latency (months)	ID testing (mg/ml)	Positive IDT	Positive ELISpot*	Post-testing OC tolerated [†]
1	47/F	0	B4 (Severe MPE †)	2	18	Clav 5/20 Beta-lactam standard‡	Clav 20	Yes	Amoxicillin Penicillin VK Cefuroxime
2	55/F	0	B4 (Severe MPE †)	2	35	Clav 5/20 Beta-lactam standard‡	Clav 20	Yes	Penicillin, Cefuroxime
3	70/M	1	B4 (Severe MPE †)	3	2	Clav 5/20 Beta-lactam standard‡	Clav 20	No	Amoxicillin Penicillin VK Cefuroxime
4	63/M	0	B4 (MPE)	-1	2	Clav 5/20 Beta-lactam standard‡	Clav 20	No	Amoxicillin Penicillin VK
5	66/F	1	B4 (MPE)	-3	5	Clav 5/20 Beta-lactam standard‡	Clav 20	No	Amoxicillin Penicillin VK Cephalexin
6	70/F	0	B4 (DRESS)	4	2	Clav 5/20 Beta-lactam standard‡	Clav 20 Ampicillin	No	Cefuroxime Penicillin VK

Abbreviations: ICH, immunocompromised; IDT, intradermal testing; OC, oral challenge; Clav, clavulanate; DRESS, drug reaction with eosinophilia and systemic symptoms; MPE, maculopapular exanthema; RegiSCAR, Registry of severe cutaneous adverse reaction diagnosis score for drug rash and eosinophilia with systemic symptoms (Final score: <2 = no case, 2-3 = possible case, 4-5 = probable case, >5 = definitive case); ELISpot, enzyme linked immunospot assay (A positive response was defined as greater than 50 SFU/million cells after background (unstimulated control) removal).

[∇] Adverse drug reactions are subclassified as type A and B reactions. Type B reactions correspond to drug hypersensitivity reactions. Type B1 includes the IgE mediated reactions, B2 the antibody mediated cytotoxicity reactions, B3, the immune complex-mediated reactions, and type B4 includes all the delayed reactions.

* ELISpot testing was performed in all patients for Amoxicillin, Augmentin and Clavulanic acid

† All delayed challenges [5-day]

‡ As per previously published methods - Patients underwent SPT/IDT followed by oral provocation as per a standardised previously published beta-lactam protocol, including validated Diater reagents (DAP; Madrid, Spain) used for the major (benzylpenicilloyl-poyl-L-lysine [PPL]), minor determinant mixtures (MDM) and clavulanate^{1,2}.

Tested IDT concentrations: benzylpenicillin, 1,000 IU/mL; benzylpenicillin, 10,000 IU/mL; Diater PPL Neat, Diater MDM, ampicillin, 25 mg/mL; Flucloxacillin, 2 mg/mL; Cephazolin 1 mg/ml, Ceftriaxone 2.5 mg/ml

† Severe MPE defined as an extensive cutaneous exanthema with more than 50% of body surface area and RegiSCAR score of 2 to 3 (possible).

1. Fernandez J, Torres MJ, Campos J, Arribas-Poves F, Blanca M, Group DA-D. Prospective, multicenter clinical trial to validate new products for skin tests in the diagnosis of allergy to penicillin. *J Investig Allergol Clin Immunol* 2013; **23**(6): 398-408.
2. Trubiano JA, Thursky KA, Stewardson AJ, et al. Impact of an Integrated Antibiotic Allergy Testing Program on Antimicrobial Stewardship: A Multicenter Evaluation. *Clin Infect Dis* 2017; **65**(1): 166-74.

Figure 1: a. Pictorial representation of a patient reporting delayed hypersensitivity to Clavulanate from tested cohort. Maculo-papular erythematous fixed eruption

b. Photographic representation of positive delayed intra-dermal clavulanate testing (24 hours post-inoculation) in the same patient reporting a delayed hypersensitivity to amoxicillin clavulanate. Tested IDT concentrations: 1. Normal Saline; 2. 2mg/ml Clavulanate; 3. 20mg/ml Clavulanate

